<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226044</url>
  </required_header>
  <id_info>
    <org_study_id>LTC-001</org_study_id>
    <nct_id>NCT00226044</nct_id>
  </id_info>
  <brief_title>Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.</brief_title>
  <official_title>Rectal and Oral Omeprazole Treatment of Gastroesophageal Reflux in Infants With Esophageal Atresia or Congenital Diaphragmatic Hernia; A Pharmacodynamic and Pharmacokinetic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of oral and rectal omeprazole treatment
      in infants with gastroesophageal reflux due to esophageal atresia or congenital diaphragmatic
      hernia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Omeprazole is a highly effective drug for the treatment of gastroesophageal reflux disease
      (GERD) in infants. Infants, aged 0-12 months, require a non-standard dose of omeprazole. Due
      to this fact extemporaneous formulations of omeprazole are administered to these infants. The
      oral bioavailability of omeprazole in nonproprietary formulations may be unpredictable and
      produce variable degrees of drug exposure. The dose range for GERD management in pediatric
      studies using omeprazole is 0.3 - 3.5 mg/kg/day.

      Dosing information, aged-specific pharmacodynamic and pharmacokinetic data are not available
      in infants, aged 0-12 months. Two adult studies at healthy volunteers suggest that an
      omeprazole suppository is an effective dosage form.This study is designed to evaluate and to
      compare the efficacy, the pharmacodynamics and the pharmacokinetics of oral and rectal
      omeprazole treatment in infants with gastroesophageal reflux disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intragastric pH, Pharmacokinetic parameters, PK-PD-relation,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic parameters</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <condition>Esophageal Atresia</condition>
  <condition>Hernia, Diaphragmatic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole suppository</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 6-12 weeks

          -  weight: 3 kg or &gt; 3 kg

          -  gastroesophageal reflux as a result of esophageal atresia or congenital diaphragmatic
             hernia.

          -  Informed consent of both parents

        Exclusion Criteria:

          -  Allergy to omeprazole

          -  Infants with gastroesophageal reflux as a result of congenital errors of CNS

          -  Changes in the co-medication during the study

          -  Participation in a study that is interfering with this study.

          -  The use of the following co-medication: alprazolam, midazolam, triazolam,
             carbamazepine, clorazepate, ciclosporin, disulfiram, phenytoin, iron, itraconazole,
             ketoconazole, voriconazole, methotrexate, ticlopidine, warfarin.

          -  Infants of the non-Caucasian race
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Tibboel, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>P. Bestebreurtje, Pharm D</last_name>
    <phone>+31355391398</phone>
    <email>pbestebreurtje@tergooiziekenhuizen.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus Medical center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. Tibboel, Prof. dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>P. Bestebreurtje, Pharm D</last_name>
      <phone>+31263786300</phone>
      <email>pbestebreurtje@tergooiziekenhuizen.nl</email>
    </contact_backup>
    <investigator>
      <last_name>A. A. van Sorge, Pharm D, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C AJ Knibbe, Pharm D, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>P. Bestebreurtje, Pharm D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2005</study_first_submitted>
  <study_first_submitted_qc>September 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omeprazole, suppository, infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Esophageal Atresia</mesh_term>
    <mesh_term>Hernia, Diaphragmatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

